$3.01 Billion is the total value of Avidity Partners Management LP's 83 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MSACW | Exit | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $0 | – | -57,770 | -100.0% | 0.00% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -31,309 | -100.0% | -0.02% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -104,653 | -100.0% | -0.02% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,140,600 | -100.0% | -0.04% | – |
| DNAB | Exit | SOCIAL CAP SUVRETTA HLDS CRP | $0 | – | -200,000 | -100.0% | -0.04% | – |
| DNAD | Exit | SOCIAL CAP SUVRETTA HLDS CP | $0 | – | -200,000 | -100.0% | -0.04% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -400,000 | -100.0% | -0.09% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -1,855,400 | -100.0% | -0.10% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -500,000 | -100.0% | -0.11% | – |
| PANA | Exit | PANACEA ACQUISITION CORP II | $0 | – | -500,000 | -100.0% | -0.11% | – |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -520,000 | -100.0% | -0.11% | – |
| GRPH | Exit | GRAPHITE BIO INC | $0 | – | -1,575,000 | -100.0% | -0.11% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -1,126,000 | -100.0% | -0.40% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -204,000 | -100.0% | -0.49% | – |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -504,000 | -100.0% | -0.58% | – |
| BNTX | Exit | BIONTECH SEsponsored ads | $0 | – | -215,400 | -100.0% | -0.70% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -258,000 | -100.0% | -0.87% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -172,000 | -100.0% | -1.08% | – |
| LLY | Exit | LILLY ELI & CO | $0 | – | -217,000 | -100.0% | -1.72% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -1,200,000 | -100.0% | -1.76% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -430,000 | -100.0% | -2.70% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -785,500 | -100.0% | -4.73% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -4,062,000 | -100.0% | -7.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.